Since TGF-β signaling pathway has a well-established role in EMT and INHBA is a secretory extracellular factor mediating TGF- β signaling, INHBA could be easily targeted by neutralizing antibody to inhibit EMT in breast cancer, which could be a novel therapeutic target especially for breast cancers with enhanced EMT phenotype. This evidence concerns the gene INHBA and breast carcinoma.